Compare Amylx Pharmaceuticals Inc (AMLX) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Huntington Bancshares Incorporated — how do they compare? Amylx Pharmaceuticals Inc trades at $23.64 (market cap $2.64B), while Huntington Bancshares Incorporated trades at $17.86 (market cap $35.93B). The key difference: Huntington Bancshares Incorporated is far larger — about 13.6× Amylx Pharmaceuticals Inc's market cap, and Huntington Bancshares Incorporated pays a 3.49% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HBAN | |
|---|---|---|
Market Cap | $2.64B | $35.93B |
Sector | Health | Financials |
52-Week High | $24.19 | $19.27 |
52-Week Low | $7.82 | $15.02 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Huntington Bancshares (HBAN) trades at $17.82, up 1.25% recently, with a bullish technical outlook and mixed earnings history. The company reported Q2 2026 EPS of $0.33, missing estimates, but revenue growth to $8.13B in 2025 supports a net income margin of 24.77%. Analysts maintain a consensus price target of $19.78, with 45% recommending Buy, amid concerns over rising deposit costs noted in recent news.
HBAN offers potential upside with a reasonable P/E of 13.68 and dividend yield, but faces risks from expense pressures and competitive banking dynamics. The stock's outlook hinges on execution of its ROTCE target of 18-19% by 2027, balancing growth opportunities with macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
